GCK polyclonal (C-term), anti-human

Background:
Hexokinases phosphorylate glucose to produce glucose-6-phosphate, thus committing glucose to the glycolytic pathway. Alternative splicing of the gene for GCK results in three tissue-specific forms of glucokinase, one found in pancreatic islet beta cells and two found in liver. The protein localizes to the outer membrane of mitochondria. In contrast to other forms of hexokinase, this enzyme is not inhibited by its product glucose-6-phosphate but remains active while glucose is abundant. Mutations in the gene have been associated with non-insulin dependent diabetes mellitus (NIDDM), also called maturity onset diabetes of the young, type 2 (MODY2); mutations have also been associated with persistent hyperinsulinemic hypoglycemia of infancy (PHHI).

Other Names:
Glucokinase, Hexokinase type IV, HK IV, Hexokinase-4, HK4, Hexokinase-D, GCK

Target/Specificity:
This GCK antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 403-433 amino acids from the C-terminal region of human GCK.

Antigen Region:
403-433

Antigen Type: Synthetic Peptide

Gene Name: GCK {ECO:0000303|PubMed:17573900, ECO:0000312|HGNC:HGNC:4195}
Gene ID: 2645
Primary Accession: P35557
NCBI Accession: NP_000153.1;NP_277042.1;NP_277043.1
Format: Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is prepared by Saturated Ammonium Sulfate (SAS) precipitation followed by dialysis against PBS.